Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Professional, scientific, and technical services symbols : Fnch save search
Human Microbiome Therapeutics Market size to grow by USD 732.95 million from 2022 to 2027, North America to account for 41% of market growth, Technavio
Published: 2024-03-06 (Crawled : 15:30) - prnewswire.com
PTCHF | $2.64 19.97% 870
|
n/a
|
| O: 4.12%
H: 0.97%
C: 0.97%
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -4.0%
H: 4.92%
C: 4.12%
EVGN | $0.7 -13.64% 63K
|
Health Technology
|
| O: 4.24%
H: 0.0%
C: -7.14%
PHGE | $0.3274 -5.51% 3.82% 130K
|
Health Technology
|
| O: 211.55%
H: 18.75%
C: -4.46%
america million therapeutics market
Human Microbiome Therapeutics Market size to grow by USD 732.95 million from 2022 to 2027, North America to account for 41% of market growth - Technavio
Published: 2024-01-08 (Crawled : 10:00) - prnewswire.com
PTCHF | $2.64 19.97% 870
|
n/a
|
| O: 3.67%
H: 0.19%
C: 0.19%
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: 6.09%
H: 3.01%
C: -4.37%
EVGN | $0.7 -13.64% 63K
|
Health Technology
|
| O: -6.76%
H: 3.38%
C: 0.3%
PHGE | $0.3274 -5.51% 3.82% 130K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: -3.15%
america million therapeutics growth market
Finch Announces Reverse Stock Split of Common Stock
Published: 2023-06-09 (Crawled : 11:00) - globenewswire.com
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -5.26%
H: 5.52%
C: 0.37%
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
Published: 2023-05-10 (Crawled : 11:00) - globenewswire.com
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -6.31%
H: 4.68%
C: 0.38%
HTGC 4 | $18.96 0.58% 0.0% 620K
|
Finance
|
| O: 1.13%
H: 1.93%
C: 0.97%
business therapeutics financial results
Global Microbiome Therapeutics Markets Report, 2021-2022 & 2023-2027 Featuring Major Players Assembly Biosciences, Finch Therapeutics, Second Genome, Evelo Biosciences and Ysopia Bioscience
Published: 2023-04-24 (Crawled : 19:00) - prnewswire.com
TOVX | News | $0.3686 -2.2% 0.27% 120K
|
Manufacturing
|
| O: 0.0%
H: 4.4%
C: 2.16%
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -9.12%
H: 6.62%
C: -0.9%
bioscience global therapeutics
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
Published: 2023-04-18 (Crawled : 00:00) - biospace.com/
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -5.18%
H: 7.24%
C: 7.14%
license hospital collaboration therapeutics agreement
Global Microbiome Therapeutics Market Analysis Report 2023: A $1.46 Billion Market by 2027 Featuring Major Players - Assembly Bio, Finch Therapeutics, Second Genome, Evelo Bio, Ysopia Bio
Published: 2023-02-10 (Crawled : 04:00) - prnewswire.com
TOVX | News | $0.3686 -2.2% 0.27% 120K
|
Manufacturing
|
| O: 2.57%
H: 0.0%
C: -6.31%
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -3.01%
H: 4.34%
C: 3.31%
global report therapeutics market
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
Published: 2023-01-24 (Crawled : 15:00) - biospace.com/
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: 11.64%
H: 8.91%
C: -11.63%
cp101 trial therapeutics
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
Published: 2022-10-24 (Crawled : 19:00) - biospace.com/
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: 3.7%
H: 12.86%
C: 10.0%
cp101 biomarker trial therapeutics infection
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
Published: 2022-08-25 (Crawled : 21:00) - globenewswire.com
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -8.01%
H: 4.86%
C: 2.43%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.78%
H: 0.65%
C: -1.44%
fin-524 therapeutics
Finch Therapeutics to Host Corporate Update Conference Call and Webcast on May 16, 2022
Published: 2022-05-09 (Crawled : 13:20) - biospace.com/
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -3.35%
H: 0.87%
C: -6.93%
conference therapeutics
Finch Therapeutics Announces Workforce Restructuring to Focus Resources on Key Development Programs
Published: 2022-04-19 (Crawled : 22:00) - biospace.com/
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -0.53%
H: 1.33%
C: -2.4%
therapeutics
Finch Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
Published: 2022-03-31 (Crawled : 21:00) - globenewswire.com
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -0.6%
H: 3.2%
C: -5.6%
therapeutics results
Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection
Published: 2022-03-01 (Crawled : 22:00) - globenewswire.com
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -7.74%
H: 0.0%
C: 0.0%
cp101 trial therapeutics infection phase 3 infections
Finch Therapeutics to Participate in the Chardan Metagenomics and Microbiome Medicines Summit
Published: 2022-02-23 (Crawled : 12:00) - globenewswire.com
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -1.84%
H: 0.0%
C: -2.7%
genomics genomic therapeutics
Finch Therapeutics Announces Additions to Senior Leadership Team
Published: 2022-02-10 (Crawled : 13:30) - biospace.com/
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: 5.5%
H: 1.55%
C: -5.22%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.92%
H: 0.0%
C: 0.0%
therapeutics
Finch Therapeutics Further Strengthens Patent Portfolio with Two New U.S. Patents Granted for FIN-211, an Investigational Microbiome Therapeutic in Development for Autism Spectrum Disorder
Published: 2022-01-06 (Crawled : 20:00) - biospace.com/
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: 0.64%
H: 3.48%
C: -2.53%
fin-211 order patent granted therapeutics ism
Finch Therapeutics Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
Published: 2021-12-20 (Crawled : 15:00) - biospace.com/
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: -0.45%
H: 11.11%
C: 8.64%
therapeutics
Finch Therapeutics to Participate in Upcoming Investor Conferences
Published: 2021-11-11 (Crawled : 16:00) - biospace.com/
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: 1.25%
H: 5.95%
C: 4.31%
conference therapeutics
Finch Therapeutics Announces Transition of Chief Medical Officer
Published: 2021-11-10 (Crawled : 12:15) - globenewswire.com
FNCH | $2.305 -17.35% -20.99% 120K
|
Professional, Scientific, and T...
|
| O: 15.94%
H: 0.19%
C: -7.44%
therapeutics
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.